<DOC>
	<DOCNO>NCT01207076</DOCNO>
	<brief_summary>This study single institution phase I study treatment patient relapse refractory leukemia age 12 year old use 90Y-AHN-12 .</brief_summary>
	<brief_title>AHN-12 Biodistribution Advanced Leukemia</brief_title>
	<detailed_description>A dose escalation schema use initial patient receive current low dose nonradiolabeled AHN-12 ( 0.20 mg/kg 1.0 mg/kg ) . If favorable biodistribution achieve patient remains negative HAMA , infusion may repeat two time ( one level increase nonradiolabeled AHN-12 time ) attempt achieve favorable biodistribution . In order achieve primary objective identifying optimal nonradiolabeled dose AHN-12 antibody patient , first patient current antibody dose achieve favorable biodistribution , next patient ( ) treat next high dose level . Patients achieve favorable biodistribution remain negative HAMA eligible therapeutic component trial . Those meeting requirement take study follow .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients must one follow histologically confirm CD45+ disease . If possible , AHN12 positivity confirm flow cytometry recent bone marrow peripheral blood sample , circulate blast present . Acute myelogenous leukemia ( AML ) , primary refractory relapse disease Refractory myelodysplastic syndrome ( MDS ) AML arise preexist MDS , refractory Acute lymphoblastic leukemia ( ALL ) , primary refractory relapse disease Chronic myelogenous leukemia ( CML ) follow blast crisis Age ≥ 12 year Karnofsky Performance Status ≥ 60 % ( 16 year old ) Lansky Play Score ≥ 60 ( &lt; 16 year ) Life expectancy &gt; 12 week opinion enrol medical provider Patients must adequate organ function Human antimouse antibody ( HAMA ) must negative ( perform patient regardless prior therapy ) . Consent adequate contraception . The effect 90YAHN12 develop fetus unknown . Source allogeneic stem cell must identify event severe myelosuppression Able give write consent . Both men woman ethnic group eligible trial . Ongoing grade 2 great nonhematologic toxicity due previously administer therapy &lt; 8 day completion therapy biologic agent Receiving investigational agent Active central nervous system ( CNS ) leukemia exclude clinical trial History allergic reaction attribute compound similar chemical biologic composition 90YAHN12 agent use study . Uncontrolled illness include , limited , uncontrolled infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement opinion enrol medical provider . Pregnant breastfeed woman exclude study 90YAHN12 , radioactive , well high dose chemotherapy total body irradiation ( TBI ) potential teratogenic abortifacient effect . Human immunodeficiency virus ( HIV ) positive patient : &lt; 60 day since autologous transplant Bone marrow cellularity &lt; 5 % ( concern myelosuppression )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>CD45+ disease</keyword>
</DOC>